(UroToday.com) In this session, Dr. Hussain discussed somatic testing in prostate cancer. Tumor genomic profiling is central to successful implementation of personalized for men diagnosed with prostate cancer.
(UroToday.com) The Advanced Prostate Cancer Consensus Conference 2021 virtual meeting session discussing PSMA in diagnostics and therapy included a presentation by Dr. Charles Ryan discussing the best use of Lutetium-PSMA and where to place it when sequencing therapies, including treatment monitoring.
(UroToday.com) In this session, Dr. Bertrand Tombal and Dr. Nick James summarized the panel responses to the consensus questions. This was followed by a discussion on the management of metastatic hormone sensitive prostate cancer (mHSPC) with input from the discussants and the panel.
(UroToday.com) In this session, Dr. Himisha Beltran discussed whether molecular markers can inform treatment decisions in mHSPC. She began by highlighting the as yet unmet clinical need for biomarkers to optimally select treatment for men with mHSPC. Specifically, biomarkers could help to select between therapies (ADT plus AR targeted agent versus docetaxel versus triplet therapy), select […]
(UroToday.com) In this session, Dr. Christopher Sweeney, discussed whether different subgroups of patients with metastatic hormone-sensitive prostate cancer (mHSPC) need different treatments. He opened by reviewing important features to consider in personalizing treatment related to the patient, clinical features, and tumor biology. Patient-specific factors to consider include their preferences, life expectancy, comorbidities, performance status, and access […]
(UroToday.com) In this session, Dr. Robert Jones discussed whether there are patients with metastatic hormone-sensitive prostate cancer (mHSPC) for whom treatment with ADT is appropriate in 2021. To frame this discussion, he considered the question from a biological and humanitarian perspective. From the biology standpoint, he posited two questions. Can we predict the absolute futility of […]
(UroToday.com) The second session of the Advanced Prostate Cancer Consensus Conference 2021 which was hosted virtually in the context of the COVID-19 pandemic focused on the role of prostate specific membrane antigen (PSMA) imaging in prostate cancer diagnostics and therapy. Following a background presentation from Dr. Derya Tilki, Dr. Stefano Fanti discussed potential pitfalls of […]
(UroToday.com) The Advanced Prostate Cancer Consensus Conference 2021 meeting session discussing PSMA in diagnostics and therapy included a presentation by Dr. Derya Tilki discussing background information of PSMA imaging and providing context for the subsequent presentations in this session. Dr. Tilki started by highlighting that PSMA is a transmembrane protein with enzymatic function as a folate […]
(UroToday.com) The Advanced Prostate Cancer Consensus Conference 2021 meeting session discussing the management of newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) included a presentation by Dr. Ian Davis regarding the evidence for “triplet therapy”, specifically ADT + docetaxel + primary additional systemic therapy.
(UroToday.com) The third and final session of the Advanced Prostate Cancer Consensus Conference 2021 which was hosted virtually in the context of the COVID-19 pandemic focused on molecular characterization of both tissue and blood, with a focus on implications for treatment with PARP inhibitors and beyond. In this context, Dr. Maha Hussain discussed the role of […]
